Search
Bentoquatam
go.drugbank.com/drugs/DB00516ApprovedBentoquatam contains bentonite, a clay, and is only effective as long as the film is visible on the skin. … Bentoquatam is a topical medication intended to act as a shield against exposure to the irritating substance urushiol, found in plants such as poison ivy or poison oak.
4-nitrophenyl-beta-D-galactoside
go.drugbank.com/drugs/DB02632ExperimentalCategories: Compounds used in a research, industrial, or household settingNOX-700
go.drugbank.com/drugs/DB05464ExperimentalNOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.
Propatyl nitrate
go.drugbank.com/drugs/DB13255InvestigationalCategories: Vasodilators Used in Cardiac DiseasesTerbutryn
go.drugbank.com/drugs/DB08215ExperimentalCategories: Compounds used in a research, industrial, or household settingEnalkiren
go.drugbank.com/drugs/DB03395ExperimentalCategories: Agents Acting on the Renin-Angiotensin SystemSPC2968
go.drugbank.com/drugs/DB06351InvestigationalIt was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult
Lefamulin
go.drugbank.com/drugs/DB12825Approved[A183206] Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.
Acellular nerve allograft
go.drugbank.com/drugs/DB30293ApprovedInvestigationalOur team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral
Encainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnThe manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991. … Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.
Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide